|Assessment Status||Rapid review complete|
|Indication||For AML in patients who are >65yrs who are not candidates for standard induction therapy|
|Rapid review commissioned||08/11/2012|
|Rapid review completed||13/12/2012|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended|
05/12/2013 Following additional commercial discussions the HSE has approved reimbursement of Decitabine (Dacogen®) in the hospital setting.